Unicycive Therapeutics, Inc.$4.05 %
Analyst Rating: Hold
Stock Details
CEO
Shalabh K. Gupta MPA
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
22
Address
4300 El Camino Real, Los Altos, CA, 94022
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Top Competitors
Income Statement
Financials
Selected Year
Revenue Estimates
EPS Estimates
Net Income Estimates
Price target for Unicycive Therapeutics, Inc. $4.05
$0
Min Forecast(+0% )
$249.61
Avg Forecast( +0% )
$325
Max Forecast(+0%)
EPS
Revenue
Institutional Holder
Loading institutional holder data...
Congress Tracker
Showing 0 of 0 results
Insider Trading of Key Employees
Showing 0 of 0 results